Daiichi Sankyo Remains Bullish On Prasugrel, Rivoglitazone Despite Safety Concerns – R&D Day

TOKYO - Daiichi Sankyo provided a status report to investors during a Feb. 21 research and development update in Tokyo. In particular, company officials responded to investor safety concerns related to two key pipeline drugs - anti-platelet drug prasugrel (CS-747) and rivoglitazone (CS-011), a PPAR agonist for type 2 diabetes